Il ruolo dell’infiammazione nella patogenesi e nel trattamento dei pazienti con dry eye Andrea Leonardi Clinica Oculistica Dipartimento di Neuroscienze Universita’ di Padova [email protected] DED Discomfort Visual disturbance Ocular surface damage Hyper osmolarity Infiammation MGD Dry Eye Disease Meibomian gland dysfunction is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface. is a chronic, diffuse abnormality of the meibomian glands, commonly characterized by terminal duct obstruction and/ or qualitative/ quantitative changes in the glandular secretion. This may result in alteration of the tear film, symptoms of eye irritation, clinically apparent inflammation, and ocular surface disease. DEWS The Ocular Surface, Apr 2007 MGD. IOVS 2011 Meccanismi principali della malattia dell'occhio secco Instabilità del film lacrimale Perdita delle celluleModifiche dei lipidi caliciformi MGD Modifiche della flora Infiammazione delle palpebre Rilascio di esterasi/lipasi Tossine Iperosmolarità Rilascio di citochine Attivazione delle MMP Danno cellulare Infiammazione Apoptosi Stimolazione nervosa Adattato da Baudouin et al. J Fr Ophthalmol 2007;30:239–46. Osmolarita’ e infiammazione produzione di lacrime •Film iperosmolare •Alterazioni morfologiche e biochimiche •Infiammazione evaporazione di lacrime Sostituti lacrimali ipotonici Controllo stress ossidativo Agenti viscosizzanti Protezione dell’epitelio Anti-inflammatori Iperosmolarita` Danno cellulare e morte Infiammazion e Liu H, IOVS 2009; Chen Z, IOVS 2008; Liu H, Exp Eye Res 2006; Li DQ, IOVS 2004 oxidative stress can be a causative factor for the development of dry eye disease Uchino Y et al. (2012) Oxidative Stress Induced Inflammation Initiates Functional Decline of Tear Production. PLoS ONE 7(10): e45805. doi:10.1371/journal.pone.0045805 Evaporazione Iperosmolarità Stress ossidativo Iposecrezione Th0 Viene prima l’instabilità del film lacrimale o l’infiammazione? DED and Inflammation •Decreased / inhibited tear production •Desiccating stress •Oxidative stress •Hyperosmolarity •Pro-inflammatory cytokines from the lacrimal gland •Blinking abnormalities mobilization and maturation of ocular surface APCs Th0 DED and Inflammation Immune cells in DED • NK cells • Mature APCs • Th1, Th17 • Dysfuncional Treg Stevenson et al. Arch Ophthalmol. 2012 Desiccating stress models DED and Inflammation Dry eye as a mucosal autoimmune disease. Stern ME, et al. Int Rev Immunol. 2013 DED and Inflammation Cytokines in DED CT Non-SS SS Increased tear levels: • INF-g, IL-1a, IL-1b, IL-6, IL-8, IL-17, TNFa, EGF, Fractalkine, IL-1RA, IP• • 10, MMP-9 TLR, ICAM-1, VEGF-C, VEGF-D CCL3, CCL4, CCL5, CXCL9, CXCL10, CCL20, CX3CL1 IL-6 concentration in tears has a strong correlation with the severity symptoms and signs (CFS, and conjunctival lissamine staining) IL-6 Yoon et al. Cornea 2007 Solomon et al. IOVS 2001 Pflugfelder et al. Curr Eye Res 1999 Tishler et al. Ophthalmology 1998 Enriquez-de- Salamanca et al. 2010 Proteomica • Analisi peprtidi lacrimali tra 500 -25.000 Da • Tecnologia complessa – HPLC – 2D-elettroforesi – SELDI-TOF-MS + ProteinChip Reader • Peptidi in Dry Eye: – Aumento di mediatori dell’infiammazione – Riduzione di proteine con funzione protettive Grus. IOVS 2006 Biomarkers in DED Over-expressed in DED Downregulated in DED: S100A6 S100A9 S100A8 S100A4 glutathione S-transferase P (GSTP1) annexin A1 (ANXA1) lipocalin 1 (LCN1) prolactin inducible protein (PIP) lactotransferrin (LTF) zinc-α-2-glycoprotein (AZGP1) galectin 7 (LEG7) cystatin S (CST4) cystatin SN (CST1) actin cytoplasmic 1 (ACTB) mammaglobin-B (SG2A1) Paziente soggettivamente molto “sofferente” Obiettività scarsa Infiammazione congiuntivale Sofferenza epiteliale corneale Sintomatologia modesta Sub basal plexus / inflammation • Increased fiber # •Sprouting • Increased tortuosity •Inflammatory cells * Benitez-del-Castillo et al. IOVS 2007, Zhang et al. Cornea 2005, Tuisku et al. Exp Eye Res 2008 Confocal Microscopy Terapia Scopo della terapia è il miglioramento e la conservazione della qualità di vita • Riduzione dei sintomi irritativi • Riduzione dello stress iper-osmolare e ossidativo • Miglioramento della funzione visiva e della fotofobia • Protezione dal danno anatomico • Numero di farmaci e di instillazioni compatibili alle esigenze quotidiane • Prevenzione e gestione dell’infiammazione Trattamento dell’occhio secco • Increase tear volume – systemic pilocarpine – volumetric tear substitutes – punctum plugs • Improve lubrication – Non Newtonian tear substitutes – Dilute tear film solutes – Increase tear turnover • Improve mucus conditions – gefarnate, Ecabet, N-Acetyl Cisteine, TSP, P2Y, 15-(S)-HETE., Rebopamide Reduce evaporation – lipid tears – lateral tarsorraphy – life style adaptation Improve/protect corneal epithelium – semi compressive eye patching – contact lenses – amniotic membrane • • • Treat the lids – Warm patches – Antibiotics (Systemic Tetracyclin & Derivatives), Macrolids – Steroids and combo – Omega 3-6 ointments – Blink exercises – loose & floppy eye lid correction • Control inflammation – – – – – – • Corticosteroids NSAIDs Cyclosporine A Omega 3 Fatty Acids Androgens Tetracyclin & Derivatives Supplement growth factors – Autologous serum eye drops – amniotic membrane – NGF algoritmo del trattamento basato sulla Cortisonici severità della Acidimalattia grassi essenziali Modifiche ambientali/dietetiche omega 3-6 Ciclosporina Trattamento di Livello 1 Tetracicline Eliminare determinati Lacrime artificiali farmaci Terapia delle palpebre Trattamento di Livello 2 Farmaci antinfiammatori Tetracicline Punctal plugs Farmaci secretagoghi Occhiali a camera umida Trattamento di Livello 3 Serum Occlusione puntale permanente Lenti a contatto Trattamento di Livello 4 Farmaci antinfiammatori per via sistemica Intervento chirurgico International Dry Eye Workshop. Ocul Surf 2007;5:163–78. Anti-Inflammatory Treatment Corticosteroids Progenitor cell proliferation Mast cell Corticosteroids Membrane phospholipids T cells Membrane Stabilization Corticosteroids Phospholipase A2 Arachidonic acid Heparin Histamine PAF Cyclooxygenase Lipoxygenase Cyclic endoperoxides Hydroperoxides Prostacyclin (PCI2) Thromboxane A2 (TXA2) Leukotrienes (LTC4, LTD4, LTE4, LTB4) Prostaglandins (PGF2, PGD2, PGE2) Corticosteroids Provide the Most Comprehensive Coverage of the Inflammatory Cascade Effect of Lipid Solubility on Glucocorticoid Penetration • The corneal epithelial levels of corticosteroid, administered both as drops and ointments, follow their lipid solubilities. • PHOSPHATE << FREE ALCOHOL < ACETATE • Inflammation disrupts the epithelial barrier and aids the penetration of the less lipid-soluble molecules. > Lipophilia < AC penetration PHARMACOKINETICS OF TOPICAL CORTICOSTEROIDS • ALCOHOLIC DERIVATIVES (intermediate lipophilia, biphasic polarity: AMPHIPHILIC MOLECULES): – – Higher penetration in AC Corneal lesions enhance drug penetration • PHOSPHATE DERIVATIVES Highly water soluble – – Low penetration in the epithelium (lipophilic) Transformed in alcohol by tear film phosphatases • HIGHLY LIPOPHILIC SUBSTITUENTS (Butirrate, Acetate, Etabonate) – Higher activity in the epithelium lower in the stroma – Surface steroids • FLUORINATED MOLECULES – Do not penetrate in AC – Surface Steroids Topical CsA in Dry Eye ■ The long-term use of topical corticosteroids is limited by potential sightthreatening side effects, such as glaucoma, cataract, and infection ■ The only drug approved by the FDA in the US for treatment of DED ■ Requires several months to produce a clinical therapeutic effect Clinical case • Female, 53. S. Sjögren. • Treated with topical, hospital preparation, of CsA baseline 3 months 7 months • Subjective and objective improvement over time • No further use of topical corticosteroids and reduced use of tear substitutes Reduction of inflammation (HLA-DR) with CsA 0.1% * p=0.022 50000 45000 Median HLA-DR (AUF) 40000 35000 30000 IKERVIS CsA 0.1% vehicle Vehicle 25000 20000 15000 10000 5000 0 Baseline Month 6 SICCANOVE Study, Santen • Treatment with topical anakinra, 2.5%, for 12 weeks was safe and significantly reduced symptoms and corneal epitheliopathy in patients with DED • These data suggest that the use of a IL-1 antagonist may have a role as a novel therapeutic option for patients with DED • LFA-1/ICAM-1 inhibition as a therapeutic target in chronic ocular T cell– mediated inflammation • SAR 1118 is a potent inhibitor of T-cell activation, adhesion, migration, proliferation, and cytokine release • Significant improvement in CFS mean change from baseline (P < .05) Il ruolo dell’infiammazione nella patogenesi e nel trattamento dei pazienti con dry eye • Patologia autoimmune localizzata generata da uno sbilanciamento tra meccanismi protettivi immunoregolatori e proinfiammatori della superficie oculare • Conserva e rispetta la superficie oculare • Corretta gestione dell’infiammazione [email protected]